Get the Stockscreener App
1.4522
0.00%
0.0278
After Hours:
1.49
0.0378
+2.60%
Tharimmune Inc stock is traded at $1.4522, with a volume of 22,567.
It is up +0.00% in the last 24 hours and down -14.45% over the past month.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
See More
Previous Close:
$1.48
Open:
$1.49
24h Volume:
22,567
Relative Volume:
0.19
Market Cap:
$3.86M
Revenue:
-
Net Income/Loss:
$-9.32M
P/E Ratio:
-0.1143
EPS:
-12.7107
Net Cash Flow:
$-7.30M
1W Performance:
+9.02%
1M Performance:
-14.45%
6M Performance:
-28.85%
1Y Performance:
-67.04%
1-Day Range:
$1.40
$1.50
1-Week Range:
$1.32
$1.50
52-Week Range:
$0.952
$6.39
Tharimmune Inc Stock (THAR) Company Profile
Name
Tharimmune Inc
Sector
Industry
Phone
302-743-2995
Address
1200 ROUTE 22 EAST, BRIDGEWATER
Compare THAR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
THAR
Tharimmune Inc
|
1.4522 | 3.65M | 0 | -9.32M | -7.30M | -12.71 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.85 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.16 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
489.52 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Tharimmune Inc Stock (THAR) Latest News
Tharimmune (THAR) Appoints Strategic Advisor to Enhance TH104 De - GuruFocus
Tharimmune Appoints Renowned Counter-Terrorism and Critical Infrastructure Expert James Gordon Liddy (CDR US Navy SEAL (Ret)) as Key Strategic Advisor Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback - Jonesboro Sun
FDA Clears Path for Tharimmune's Military Fentanyl Defense Drug as Navy SEAL Commander Joins Advisory Team - Stock Titan
Tharimmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Tharimmune, Inc. SEC 10-Q Report - TradingView
Tharimmune appoints new executive chairman By Investing.com - Investing.com India
Tharimmune appoints new executive chairman - Investing.com Australia
Tharimmune IncAppoints Vincent Lopriore As Executive ChairmanSEC Filing - marketscreener.com
Tharimmune (THAR) Reports Promising Phase 1 Results for TH104 Bu - GuruFocus
Tharimmune (THAR) Advances TH104 as Key Medical Countermeasure | - GuruFocus
Tharimmune advances opioid prophylaxis drug TH104 - Investing.com
Tharimmune advances opioid prophylaxis drug TH104 By Investing.com - Investing.com South Africa
Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback - Weatherford Democrat
Tharimmune's New Drug Breakthrough: FDA Fast-Tracks Military Protection Against Weaponized Fentanyl - Stock Titan
Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences - Chronicle-Tribune
Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors - Bluefield Daily Telegraph
Stocks of Tharimmune Inc (THAR) are poised to climb above their peers - Sete News
Breakthrough Drug TH104 Clinical Data Selected for Two Premier Medical Conferences DDW and EASL - Stock Titan
Tharimmune Appoints Clay Kahler And Gary Stetz To Board - citybiz
Tharimmune (THAR) Expands Board with New Appointments | THAR Sto - GuruFocus
Tharimmune expands board with two new directors By Investing.com - Investing.com India
Tharimmune expands board with two new directors - Investing.com
Tharimmune Adds $500M Success Story Entrepreneur and Financial Expert to Board Leadership - Stock Titan
Tharimmune Inc’s latest rating changes from various analysts - knoxdaily.com
Tharimmune Inc (THAR) Stock: Uncovering 52-Week Market Trends - investchronicle.com
These Numbers Show Just How Powerful Tharimmune Inc (NASDAQ: THAR) Stock Is - Stocksregister
Tharimmune expands board, appoints new directors By Investing.com - Investing.com Nigeria
Tharimmune expands board, appoints new directors - Investing.com
FDA Nods to Tharimmune’s Countermeasure for Opioid Threats By Investing.com - Investing.com South Africa
FDA Nods to Tharimmune’s Countermeasure for Opioid Threats - Investing.com Australia
Now Is The Time To Build A Position In Tharimmune Inc (NASDAQ:THAR) - Marketing Sentinel
Observations on the Tharimmune Inc (NASDAQ:THAR) Growth Curve - uspostnews.com
Tharimmune (THAR) Advances TH104 with FDA Feedback on New Drug A - GuruFocus
Tharimmune (THAR) Advances TH104 with FDA Feedback on New Drug Application | THAR Stock News - GuruFocus
Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback - The Joplin Globe
FDA Clears Path for Tharimmune's Military-Grade Fentanyl Defense Drug: No New Trials Needed - Stock Titan
Tharimmune announces board retirements ahead of annual meeting - Investing.com
Tharimmune announces board retirements ahead of annual meeting By Investing.com - Investing.com South Africa
Press Release Distribution & PR Platform - ACCESS Newswire
Tharimmune (THAR) Expands Board with New Appointment | THAR Stoc - GuruFocus
Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors - Chronicle-Tribune
Healthcare Investment Expert Managing $150M Portfolio Strengthens Tharimmune's Strategic Leadership - Stock Titan
Tharimmune reports data on new biparatopic biologics - BioWorld MedTech
THAR stock touches 52-week low at $1.12 amid sharp annual decline By Investing.com - Investing.com South Africa
THAR stock touches 52-week low at $1.12 amid sharp annual decline - Investing.com Australia
Tharimmune Reports Preclinical Data for Dual-Target Biologics - MarketScreener
Tharimmune Announces Positive Data With Novel Biparatopic PD-1/VEGF & Multispecific HER2/HER3 Biologics Leveraging Proprietary Epiclick(TM) Technology - MarketScreener
Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology - Weatherford Democrat
Breakthrough Cancer Drug Shows Superior Design: Tharimmune's Dual-Target Biologic Outperforms Competition - Stock Titan
Tharimmune Inc Stock (THAR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tharimmune Inc Stock (THAR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MILBY RANDY | CEO |
Dec 19 '24 |
Buy |
2.12 |
4,600 |
9,752 |
17,534 |
| Appajosyula Sireesh | Chief Operating Officer |
Nov 13 '24 |
Buy |
2.02 |
5,000 |
10,096 |
10,758 |
| MILBY RANDY | CEO |
Oct 08 '24 |
Buy |
2.09 |
2,500 |
5,221 |
12,934 |
| Appajosyula Sireesh | Chief Operating Officer |
Oct 08 '24 |
Buy |
1.93 |
5,000 |
9,650 |
16,364 |
1.89%
3.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):